Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Recurrence 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Dexamethasone 43Cyclophosphamide 38fludarabine phosphate 27Cytarabine 26Rituximab 24Methotrexate 21Lenalidomide 21Bortezomib 21Calcium Dobesilate 20fludarabine 19Peripheral Blood Stem Cell Transplantation 19Whole-Body Irradiation 16Mycophenolic Acid 16pembrolizumab 15Gemcitabine 15Etoposide 15pomalidomide 14Melphalan 14Vincristine 13Filgrastim 13Busulfan 13Tacrolimus 12Cyclosporine 12Carboplatin 12Paclitaxel 11carfilzomib 10durvalumab 9Doxorubicin 9Cetuximab 9Brentuximab Vedotin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Recurrence × Hyaluronoglucosaminidase × Clear all
NCT05498220 2026-04-16

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Terminated
5 enrolled 13 charts
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡